Filing Overview
Registrant: Blue Water Biotech, Inc. (now identified in the request metadata as Onconetix, Inc.); Nasdaq ticker BWV. This Form 8-K reports actions taken on May 31, 2023, including adoption of an employee retirement plan, a bylaw amendment, and results of the 2023 annual meeting of stockholders.
Material Corporate Actions
- 401(k) plan: The Board adopted a 401(k) Safe Harbor Non-Elective Plan effective July 1, 2023. Substantially all employees, including named executive officers, may participate. The Company will contribute 3% of eligible employees’ gross pay. Contributions vest immediately, subject to a three-month waiting period for new hires.
- Bylaw amendment: Effective May 31, 2023, the quorum requirement for stockholder meetings was reduced from a majority to one-third of the voting power of outstanding shares entitled to vote. No other bylaw changes were reported.
Annual Meeting Results
As of the record date, 15,878,150 shares were entitled to vote, and 9,971,461 shares were present or represented by proxy.
| Proposal | Result | Vote detail |
|---|---|---|
| Election of James Sapirstein as Class II director | Approved | 6,207,510 for; 656,947 withheld; 3,107,004 broker non-votes |
| Amendment to 2022 Equity Incentive Plan | Approved | Share reserve increased by 550,000, from 2,600,000 to 3,150,000 shares; 6,191,117 for; 659,202 against; 14,138 abstaining; 3,107,004 broker non-votes |
| Ratification of independent auditor | Approved | Mayer Hoffman McCann P.C. ratified for fiscal 2023; 9,717,035 for; 248,537 against; 5,889 abstaining |
Financial Metrics and Outlook
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, balance-sheet data, or financial guidance. It also does not provide a quantified estimate of the future cost of the 401(k) contribution obligation.
Investor Verification Items
- Verify the registrant’s corporate name and ticker, given the filing identifies Blue Water Biotech, Inc. while the request metadata identifies Onconetix, Inc.
- Assess the expected expense and cash impact of the mandatory 3% 401(k) contributions beginning July 1, 2023.
- Review the amended bylaws for the practical effect of the reduced one-third stockholder-meeting quorum.
- Evaluate potential dilution from the additional 550,000 shares authorized under the 2022 Equity Incentive Plan.
- Confirm the term and responsibilities of the re-elected Class II director and the scope of the auditor’s engagement.